LifeScience Antibody Drug Conjugates
Alphamab Oncology and CSPC’s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targ...
October 21, 2025 | News
Sichuan Kelun-Biotech’s Trastuzumab Botidotin Approved in China for HER2-Positive Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor recep...
October 20, 2025 | News
Merck to Acquire JSR’s Chromatography Business to Strengthen Downstream Bioprocessing Portfolio
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions JSR’s innovative Amsphe...
October 16, 2025 | News
Mabwell’s CDH17-Targeting ADC 7MW4911 Receives NMPA IND Clearance for Advanced Solid Tumours
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...
October 15, 2025 | News
Thousand Oaks Biologics Secures EU QP Declaration for ADC Manufacturing Facility in Shanghai
Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person ...
October 14, 2025 | News
Turning Signals into Cures: The Big Data Blueprint for Cell Therapy Factories
Cell therapy manufacturing is entering a data-driven era, as the industry grapples with complex production processes, high costs, and the need for personal...
October 07, 2025 | Analysis
WuXi XDC Co-Hosts 2025 BPD Singapore Summit Showcasing Innovation in Bioconjugates and Global Biopharma Collaboration
The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully conclude...
September 30, 2025 | News
WuXi Biologics Launches TrueSite TI™, a Next-Generation Targeted Integration Cell Line Platform Redefining Biologics Development
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone scre...
September 29, 2025 | News
Hengrui Pharma Grants Glenmark Exclusive Global Licence for HER2-Targeted ADC Trastuzumab Rezetecan
Hengrui Pharma, a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced that it has entered ...
September 25, 2025 | News
Eli Lilly to Invest $5 Billion in New Virginia API and Bioconjugate Manufacturing Facility
New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other ad...
September 17, 2025 | News
China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...
September 17, 2025 | News
Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate
Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...
September 16, 2025 | News
Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...
September 16, 2025 | News
Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...
September 12, 2025 | News
Most Read
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
